Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.

Krista B Goodman, Michael J Bury, Mui Cheung, Maria A Cichy-Knight, Sarah E Dowdell, Allison K Dunn, Dennis Lee, Jeffrey A Lieby, Michael L Moore, Daryl A Scherzer, Deyou Sha, Dominic P Suarez, Dennis J Murphy, Mark R Harpel, Eric S Manas, Dean E McNulty, Roland S Annan, Rosalie E Matico, Benjamin K Schwartz, John J Trill, Thomas D Sweitzer, Da-Yuan Wang, Paul M Keller, John A Krawiec, Michael C Jaye

文献索引：Bioorg. Med. Chem. Lett. 19(1) , 27-30, (2009)

全文：HTML全文

摘要

Endothelial lipase (EL) activity has been implicated in HDL catabolism, vascular inflammation, and atherogenesis, and inhibitors are therefore expected to be useful for the treatment of cardiovascular disease. Sulfonylfuran urea 1 was identified in a high-throughput screening campaign as a potent and non-selective EL inhibitor. A lead optimization effort was undertaken to improve potency and selectivity, and modifications leading to improved LPL selectivity were identified. Radiolabeling studies were undertaken to establish the mechanism of action for these inhibitors, which were ultimately demonstrated to be irreversible inhibitors.